A Registered Cohort Study on Wilson’s Disease

Learn more about:
Related Clinical Trial
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 A Phase I/II Study of VTX-801 in Adult Patients With Wilson’s Disease Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Study of Retinal Vascular Parameters in Patients With Wilson’s Disease Evaluation of Patients With Liver Disease ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment Establishment of Human Cellular Disease Models for Wilson Disease Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson’s Disease-related Liver Failure The Individual Therapy for Patients With Wilson’s Disease Study of Zinc for Wilson Disease Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson’s Disease Study of Tetrathiomolybdate in Patients With Wilson Disease Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months WILSTIM – DBS (WILson STIMulation – Deep Brain Stimulation) Efficacy and Safety Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis Inhibitory rTMS in Dystonic Wilson Patients Natural History of Wilson Disease A Registered Cohort Study on Wilson’s Disease sCD163 and sMR in Wilsons Disease – Associations With Disease Severity and Fibrosis Cohort Research on Wilson’s Disease Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson’s Disease Patients Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients

Brief Title

A Registered Cohort Study on Wilson's Disease

Official Title

A Registered Cohort Study on Wilson's Disease

Brief Summary

      The aim of this study is to determine the clinical spectrum and natural progression of
      Wilson's Disease in a prospective multicenter natural history study, to assess the clinical,
      genetic, epigenetic features and biomarkers of patients with Wilson's Disease to optimize
      clinical management.
    



Study Type

Observational


Primary Outcome

The change of Unified Wilson's Disease Rating Scale (UWDRS)


Condition

Wilson's Disease

Intervention

No intervention

Study Arms / Comparison Groups

 Patients with the genetic diagnosis of Wilson's Disease
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

2000

Start Date

July 1, 2019

Completion Date

December 2049

Primary Completion Date

December 2039

Eligibility Criteria

        Inclusion Criteria:

          -  Patients with the genetic diagnosis of Wilson's Disease

          -  Asymptomatic Wilson's Disease carriers

          -  Relatives of Wilson's Disease patients or carriers

          -  Unrelated healthy controls

          -  Participants or Parent(s)/legal guardian(s) willing and able to complete the informed
             consent process

        Exclusion Criteria:

        * Participants are unable to comply with study procedures and visit schedule
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

, 86-0591-87982772, [email protected]

Location Countries

China

Location Countries

China

Administrative Informations


NCT ID

NCT04012658

Organization ID

MRCTA,ECFAH OF FMU[2019]197


Responsible Party

Sponsor-Investigator

Study Sponsor

Wan-Jin Chen


Study Sponsor

, , 


Verification Date

September 2019